VANI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vivani Medical Inc (VANI) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has weak financial performance, and no strong trading signals. It is better to wait for clearer bullish indicators or improved fundamentals before considering an entry.
The technical indicators show a bearish trend with moving averages (SMA_200 > SMA_20 > SMA_5). The MACD is slightly positive but contracting, and RSI is neutral at 42.692. Key support levels are at 0.952 and 0.905, while resistance levels are at 1.103 and 1.149.
The analyst believes the company's product NPM-139 has potential due to its unique positioning for efficacy comparable to Wegovy with less frequent administration.
The stock is down 1.92% in pre-market trading. Financial performance is weak, with no revenue growth, negative net income, and declining EPS. There are no recent news catalysts, no significant insider or hedge fund activity, and no recent congress trading data.
In 2025/Q4, the company reported no revenue growth (0% YoY), a net income loss of -$6.63M (up 9.64% YoY), and a decline in EPS to -0.09 (-18.18% YoY). Gross margin remained at 0%.
H.C. Wainwright analyst Yi Chen lowered the price target from $4 to $3.50 while maintaining a Buy rating, citing an increased share count. The analyst views the company's product pipeline positively but acknowledges challenges.
